Montalbano John S.

Director Montalbano buys 20,000 ABCL shares at $4.77; holdings rise to 241,000 shares amid 160.6% annual revenue growth and -$43.2M net loss.

Director John S. Montalbano purchased 20,000 shares of AbCellera Biologics Inc. at $4.77 on 2026-05-14, increasing his holdings from 221,000 to 241,000 shares. The transaction occurs with the stock trading at $4.06 (37.7% below its 52-week high of $6.52), though the 90-day change shows +28.1% appreciation. AbCellera reported latest-quarter revenue of $8.3M with annual revenue growth of +160.6%, but remains unprofitable with net income of -$43.2M over the most recent full fiscal year, creating a fundamental tension between growth trajectory and profitability. Montalbano's prior three measurable purchases at this ticker yielded mixed 90-day outcomes ranging from -9.8% to +6.1%, with outcomes distributed between net positive and net negative performance.

Director Montalbano buys 50,000 shares of ABCL at $3.57 (29.2% increase to 221,000 holdings) amid -41.0% YTD decline and -$57.1M annual net loss.

Montalbano's purchase of 50,000 shares for $178,460.00 represents a substantial 29.2% increase to his ABCL stake, now totaling 221,000 shares. The timing follows steep near-term price deterioration: the stock has fallen -41.0% from its 52-week high of $6.17 and -36.9% over the past 30 days. However, this buy occurs in the context of fundamental headwinds—the company reported annual net income of $-57,119,000.00, annual revenue decline of -24.2%, and latest quarterly revenue of only $8,955,000.00. His prior two measurable buys at ABCL (conducted in March 2025) generated positive 90-day returns of +6.1% and +3.3%, establishing a pattern of well-timed entry points at this ticker, yet current stock weakness and material unprofitability warrant scrutiny into whether this purchase represents confidence or reflects the typical market dynamics of accumulation at depressed levels by insider decision-makers.

Director Montalbano buys 25,000 ABCL shares at $2.30; stock down -55.6% from 52-week high of $4.96

Director John S. Montalbano purchased 25,000 shares of AbCellera at $2.30 on 2025-03-10, increasing his holdings by 17.1% to 171,000 shares post-transaction. This purchase follows another buy by the same director four days prior on 2025-03-06, suggesting continued accumulation at depressed price levels; the stock is currently trading at $2.20, down -55.6% from its 52-week high of $4.96 and -29.0% over the past 30 days. AbCellera faces significant headwinds—the company reported Revenue of $6.5M in the latest quarter with a Net income loss of $-51.1M, annual revenue declining -24.2%, and the company was unprofitable over its most recent full fiscal year, suggesting the recent price weakness may reflect fundamental deterioration rather than a temporary dislocation. The director's near-simultaneous purchases at these low prices warrant observation as a potential contrarian signal, though his prior same-ticker trades remain too recent to evaluate timing pattern.

Director Montalbano bought 60,000 ABCL shares at $2.34 on 2025-03-06; stock down 42.9% from 52-week high, prior buys at this ticker showed 90d gains.

Montalbano purchased 60,000 shares at $2.34, increasing his holdings by 69.8% to 146,000 shares. The buy occurred while the stock trades at $2.33, down 42.9% from its 52-week high of $4.08 and down 31.1% over the prior 30 days. His prior two purchases at ABCL (2023-11-06 and 2023-11-08) both delivered positive 90-day returns (8.0% and 16.1%), establishing a pattern of well-timed accumulation at this ticker. However, the company reported negative net income of $-51.1M in the latest quarter, annual revenue declined 24.2% year-over-year, and profitability remains elusive. The confluence of significant insider accumulation at depressed prices alongside deteriorating fundamentals warrants investigation into whether this reflects contrarian conviction or misalignment between insider actions and financial reality.